Hedia
Hedia is a digital therapeutics company specializing in diabetes management through its flagship product, Hedia Diabetes Assistant (HDA), a CE-marked Class IIb medical device designed to support insulin-requiring diabetes patients. The company offers a personalized insulin dosing solution developed in collaboration with patients and healthcare professionals to improve blood glucose stability and overall health outcomes. Hedia's product is integrated with partners like Glooko and is available in multiple European countries. The company focuses on clinical validation, with studies showing reduced hypoglycemia risk and improved glycemic control. Hedia operates a B2B2C model, distributing its app through healthcare providers and collaborating with clinics, hospitals, and device manufacturers to enhance diabetes care. The company is headquartered in Copenhagen, Denmark, and is actively expanding its product pipeline and partnerships to advance digital diabetes therapeutics.
Hedia
Hedia is a digital therapeutics company specializing in diabetes management through its flagship product, Hedia Diabetes Assistant (HDA), a CE-marked Class IIb medical device designed to support insulin-requiring diabetes patients. The company offers a personalized insulin dosing solution developed in collaboration with patients and healthcare professionals to improve blood glucose stability and overall health outcomes. Hedia's product is integrated with partners like Glooko and is available in multiple European countries. The company focuses on clinical validation, with studies showing reduced hypoglycemia risk and improved glycemic control. Hedia operates a B2B2C model, distributing its app through healthcare providers and collaborating with clinics, hospitals, and device manufacturers to enhance diabetes care. The company is headquartered in Copenhagen, Denmark, and is actively expanding its product pipeline and partnerships to advance digital diabetes therapeutics.
TL;DR
Product: Hedia Diabetes Assistant — CE-marked Class IIb digital therapeutic for insulin-requiring diabetes
Headquarters: Copenhagen, Denmark
Business model: B2B2C: app distribution via healthcare providers and partnerships; freemium/subscription cited
Clinical focus: Clinical validation with studies reporting reduced hypoglycemia risk and improved glycemic control
Recent financing: €3M seed extension announced Feb 2024 (reported)
Company Overview
Problem Domain
Insulin-requiring diabetes self-management and glycemic control
Founded
2016
Industry
Digital Therapeutics / Healthcare Software
Funding Track Record
€3,000,000
Seed extension announced to support commercialization and expansion
Investor Signal
“EASME; Startupbootcamp Digital Health Berlin”